Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Geisinger Health has teamed up with Swiss-based device-maker Medacta International in a pilot program guaranteeing lifetime coverage of hip replacement costs for Geisenger patients.
Latest From Market Access
The US Centers for Medicare and Medicaid Services March 16 said it will cover next-generation sequencing diagnostic laboratory tests for advanced cancers, broadening its final determination to cover use in relapsed, refractory and stage III cancers, while dropping "coverage with evidence development" conditions.
Glooko says it has found more success by pitching its diabetes management app to self-insured employers and to payers as a tool they can implement to reduce spending, rather than by pursuing reimbursement in the traditional way. It's one model for the digital-health sector in the current health-care environment.
On this week's podcast, we discuss US medtech policy developments from the Centers for Medicare and Medicaid Services, the Federal Trade Commission, FDA and the Supreme Court.
The office that oversees Medicare coverage decisions and policies has restructured in an effort to improve predictability and efficiency in evaluating new technologies. Medtech industry leaders say more reforms are needed.
A wide variety of devices that could either serve as pain-relief substitutes for opioids, help manage opioid addictions or tackle distribution issues with the overly prescribed medications are facing reimbursement challenges at the US Centers for Medicare and Medicaid Services.
India’s firebrand pharma pricing authority chief has been transferred out amid sharply polarized views on either side of the debate around his controversial stint.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.